Jonathan Mark Hopper - 18 Feb 2026 Form 4 Insider Report for Vericel Corp (VCEL)

Reporting relationship: Chief Medical Officer
Issuer ticker: VCEL
Reported as of: 18 Feb 2026
Net transaction value: -$36,737
SEC form: 4
Accepted by SEC: 20 Feb 2026, 16:06:10 UTC
Prior SEC filing: 13 Feb 2026
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper

Key filing fact

Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 20 Feb 2026.

Key facts

This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
7 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 20 Feb 2026, 16:06.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: -$36,737.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001626325 Primary reporting owner

Hopper Jonathan Mark

Relationship: Chief Medical Officer
Address: 64 SIDNEY STREET, CAMBRIDGE
Signature: /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Signature date: 20 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VCEL transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,000
Change %: +4.5%
Price
Shares after: 69,684
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1, F2, F3

VCEL transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,325
Change %: +3.3%
Price: $0.000000
Shares after: 72,009
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F3, F4

VCEL transaction

Common Stock

Tax liability

Transaction value: $36,737
Shares: -982
Change %: -1.4%
Price: $37.41
Shares after: 71,027
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F3, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VCEL transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: +3,000
Change %
Price
Shares after: 3,000
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price
Footnotes: F2, F6, F7

VCEL transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: +2,325
Change %
Price
Shares after: 0
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,325
Exercise price
Footnotes: F4, F6, F7, F8

VCEL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $38.17
Footnotes: F9

VCEL transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +14,000
Change %
Price: $0.000000
Shares after: 14,000
Date: 19 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,000
Exercise price
Footnotes: F6, F7, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

Footnote F2

The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

Footnote F3

These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Footnote F4

The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022.

Footnote F5

These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

Footnote F6

Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

Footnote F7

No expiration date for this type of award.

Footnote F8

The Fair Market Value of the vested derivative securities is $37.41 per share.

Footnote F9

These options shall begin vesting on February 19, 2026 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

Footnote F10

These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2027. The remaining RSUs will vest in annual installments on February 19, 2028, February 19, 2029, and February 19, 2030, respectively.